SCHEMBL31286699

SCHEMBL31286699

COC(=O)CN1CCN(CCOCCOCC(=O)OC(C)(C)C)CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.41
CACNA1H O95180 1/20 0.35
DRD2 P14416 5/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
HRH1 P35367 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM1 P11229 1/20 0.33
CHRM3 P20309 1/20 0.33
SIGMAR1 Q99720 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
WNT1 P04628 1/20 0.32
GSK3B P49841 1/20 0.32
DYRK1A Q13627 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31286711 0.90 SCN9A (0.44) SCN9ACACNA1HDRD2HRH1SIGMAR1
SCHEMBL20572924 0.83 USP2 (0.43) SCN9ACHRM2CHRM4CHRM1CHRM3
SCHEMBL24809231 0.83 MEN1 (0.46) SCN9AMEN1KMT2ANPC1RAB9A
SCHEMBL31286849 0.83 HRH1 (0.41) MEN1KMT2AHRH1
SCHEMBL31286870 0.81 SCN9A (0.44) SCN9AMEN1KMT2AGAAMAPT
SCHEMBL20305593 0.81 SCN9A (0.43) SCN9ADRD2MEN1KMT2AHRH1
SCHEMBL6450457 0.81 CHRM2 (0.38) CACNA1HDRD2MEN1KMT2ANPC1
SCHEMBL7604209 0.81 USP2 (0.43) CHRM2CHRM4CHRM1CHRM3SMN1; SMN2
SCHEMBL15874982 0.81 MEN1 (0.46) SCN9AMEN1KMT2ANPC1RAB9A
SCHEMBL30097332 0.81 MEN1 (0.46) SCN9AMEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747248-A1 COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION Institute of Cancer Research: Royal Cancer Hospital (The) (GB) 2026-05-27 EP disclosed
WO-2025022093-A1 COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2025-01-30 WO disclosed